Evaluation of costs and performance of meningitis surveillance in Chad

PI: Ulla Griffiths
Funding: Bill and Melinda Gates Foundation through Agence de Médecine Préventive

Chad, like other countries in the African meningitis-belt region, has historically been ravaged by recurring meningitis outbreaks, mainly caused by serogroup A Neisseria (NmA).  A new conjugate vaccine (MenAfriVac®) developed to combat this strain has shown to be effective in decreasing the transmission of the NmA bacteria.  In Chad meningitis is largely monitored using a passive strategy, with only few districts employing active case-based surveillance.  Since the introduction of MenAfriVac®, Chad and other countries have acknowledged the need to implement a stronger and more sensitive surveillance system. However, the approach needs to be affordable and tailored to country circumstances. The Bill and Melinda Gates Foundation commissioned the present study with the aim of obtaining baseline cost estimates that can be used for extrapolation to determine resources needed for improving and scaling up meningitis surveillance in the African meningitis belt. The study is conducted in collaboration with Centre de Support en Santé Internationale in Chad and Agence de Médecine Préventive (AMP) in France. AMP is undertaking a similar study in Niger. The results from the two country studies will be used for developing a model for predicting the costs of implementing and maintaining various meningitis surveillance strategies.

Back